Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability

PHASE3TerminatedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
PainChronic PainLow Back PainNeuropathic PainNociceptive Pain
Interventions
DRUG

Tapentadol Prolonged Release

"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."

Trial Locations (27)

Unknown

BE004, Bruges

BE003, Charleroi

BE002, Edegem

BE001, Liège

CZ001, Brno

FR004, Thionville

FR001, Toulouse

DE005, Albstadt

DE001, Berlin

DE003, Berlin

DE006, Kiel

DE004, Leipzig

DE008, Leipzig

DE007, Stuttgart

NL002, Alkmaar

NL004, Doetinchem

NL003, Eindhoven

NL001, Tiel

PL002, Krakow

PL001, Poznan

ES006, Cadiz

ES001, Granada

ES003, Málaga

ES004, Seville

ES005, Valencia

CH001, Basel

CH002, Sankt Gallen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Grünenthal GmbH

INDUSTRY

NCT00986258 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability | Biotech Hunter | Biotech Hunter